CARIS LIFE SCIENCES, INC. Operating Cash Flow
CARIS LIFE SCIENCES, INC. (CAI) reported Operating Cash Flow of $61.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $28.48M, a 290.74% increase year-over-year.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $32.88M.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $44.78M.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $62.42M.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was $83.16M.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$245.20M.
- CARIS LIFE SCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$276.10M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $61.35M 10-Q · filed 2026-08-05 | $106.13M derived: sum of 3 quarters · filed 2026-08-05 | $168.56M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $32.88M 10-Q · filed 2026-05-08 | $77.66M derived: sum of 2 quarters · filed 2026-05-08 | $140.08M derived: sum of 3 quarters · filed 2026-05-08 | $147.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $44.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $107.20M derived: sum of 2 quarters · filed 2026-03-03 | $114.49M derived: sum of 3 quarters · filed 2026-08-05 | $83.16M 10-K · filed 2026-03-03 |
| 2025-09-30 | $62.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $69.71M derived: sum of 2 quarters · filed 2026-08-05 | $38.38M 10-Q · filed 2025-11-05 | -$546.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$24.05M 10-Q · filed 2026-08-05 | -$62.97M derived: sum of 3 quarters · filed 2026-08-05 | -$132.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$31.34M 10-Q · filed 2026-05-08 | -$70.26M derived: sum of 2 quarters · filed 2026-05-08 | -$139.69M derived: sum of 3 quarters · filed 2026-05-08 | |
| 2024-12-31 | -$38.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$108.35M derived: sum of 2 quarters · filed 2026-03-03 | -$245.20M 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$69.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$206.28M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | -$136.85M 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | -$276.10M 10-K · filed 2026-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |